Clinical Trial Detail

NCT ID NCT03406156
Title A Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Excluding Those With the 17p Deletion, to Evaluate Debulking Regimens Prior to Initiating Venetoclax Combination Therapy
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors AbbVie
Indications

CLL/SLL

chronic lymphocytic leukemia

Therapies

Bendamustine + Obinutuzumab

Obinutuzumab + Venetoclax

Bendamustine

Age Groups: adult senior

No variant requirements are available.